A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Single and Multiple Ascending Dose Study of AS902330 (rhFGF-18) Administered Intra-Articularly in Patients With Knee Primary Osteoarthritis Who Are Candidates for Total Knee Replacement.

Trial Profile

A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Single and Multiple Ascending Dose Study of AS902330 (rhFGF-18) Administered Intra-Articularly in Patients With Knee Primary Osteoarthritis Who Are Candidates for Total Knee Replacement.

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Mar 2016

At a glance

  • Drugs Sprifermin (Primary)
  • Indications Osteoarthritis
  • Focus Adverse reactions; Biomarker; First in man
  • Sponsors Merck KGaA
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 Mar 2016 Results published in the Clinical and Experimental Rheumatology
    • 14 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top